Commercial License for CHOK1BN

The antibody sequence is crucial for patent applications (distinguish your antibody from others), recombinant antibody expression, antibody engineering (humanization & affinity maturation), and more. Biointron offers a high-quality hybridoma sequencing service, for the sequencing of variable regions of...

Bispecific antibodies represent a key component of the next-generation of antibody therapy. Bispecific antibodies can target more than two different antigens at the same time. For instance, they can simultaneously bind tumor cell receptors while recruiting cytotoxic immune cells.Biointron has expressed tho...

Recombinant antibody technologies are rapidly becoming available and showing considerable clinical success. However, murine monoclonal antibodies may induce immunogenic responses, potentially limiting their application for humans. Humanized antibodies can overcome these problems and are considered to be a ...

FCMES - AM® (Full Coverage Mammalian Expression System) is Biointron's proprietary platform for affinity maturation. Each amino acid in the CDR region will be mutated to the other 18 amino acids (except Cysteine) with equal ratios. The clones will be expressed in a mammalian system and an ELISA binding ass...

Biointron's fucose-free host cell CHOK1BN-Fut8KO can be used for industrial production following antibody characterization and functional verification. Compared to the unmodified CHOK1BN cell line, the antibody produced by the modified cell line not only achieves afucosylation but also maintains consistenc...

Biointron provides a stable cell line development service for bioproduction purposes. Our stable cell line service, based on ECACC licensed CHO-K1 cells, aims to provide a high-yield guaranteed and speedy timeline to meet your downstream applications.

Highlights: • High-Yield: >5 ...

Producing therapeutic antibodies or proteins in large quantities is required for many applications, including in vitro studies, in vivo animal studies, and pre-clinical trials. Biointron' s large-scale Producing services offers scaled-up production of recombinant antibodies/ proteins from hundreds of milli...

These packages are designed to offer cost-effective, time-saving solutions to meet small-scale rush needs in as fast as 8 days, with a sizable production capability for more than 5K samples.

Now adding RushMab-Gene! With only 4 days, we can have 100ug transfection-grade expr...

Expression systems utilizing mammalian cells for recombinant protein manufacture introduces proper protein folding, post-translational modifications, and protein assembly, which are important for producing proteins of complete biological activity, and thus is in high demand in the therapeutic development a...

Biointron’s catalog products for in vivo research can be found at Abinvivo, where we have a wide range of: • Benchmark Positive Antibodies • Isotype Negative Antibodies • Anti-Mouse Antibodies • Bispecific Antibodies • Antibody-Drug Conjugates • Dilution Buffers

Biointron's high-throughput antibody production provides the most cost-effective option for recombinant antibodies, where you may choose to deliver either supernatant or purified antibodies (ug to gram level). From gene synthesis to purified antibodies (IgG, scFv, VHH, etc.), it takes as fast as 2 weeks. A...

SdAb or VHH is a promising next-generation therapeutic antibody technology for cancer immunotherapy and other applications. Biointron is a well-recognized leader in the field of single domain antibody discovery. Based on our advanced phage display technology and high-throughput antibody expression platform...

Take a look at our products in this handy brochure!

Biointron's latest webinar features Shun Zhou, Ph.D, the R&D Director at Cyagen: “Accelerating Antibody Discovery with Fully Human Antibody Mouse HUGO-Ab™ and Single B Cell Screening Technology AbDrop™”

This topic explores the revolutionary potential of the genome-edited mouse HUGO-Ab, where endogenous VH and VL genes are replaced by fully human VH and VL genes in situ, enabling the generation of fully human antibody molecules. When combined with microfluidic technology-enhanced single B cell screening, this approach allows for the high-throughput and efficient discovery of antibody drug molecules.

This report aims to explore the events and trends of the biopharmaceutical industry in Q3 (July, August, September).
https://www.biointron.com/industry-trends/biointron-insights-antibody-industry-report-q3-2024-insights-trends-analysis.html

This quarter saw an increase in research trends in higher drug–antibody ratios for antibody-drug conjugates (ADCs), with promising approaches to address the problem of high hydrophobicity. Positive results in various clinical trials for anti-TIGIT therapies have also excited the field, with safety and pharmacovigilance at the center after numerous failures. Here, we give an example of a promising monoclonal antibody in development.

To learn more, download the trends report here: https://www.biointron.com/industry-trends/biointron-insights-antibody-industry-report-q3-2024-insights-trends-analysis.html